Zilia(AXIA-P)
RIO DE JANEIRO, BrazilBiotechnology
Focus: Zilia is a publicly traded Brazilian biotech company specializing in devices for assessment of biomarkers in the eye, with a focus on ophthalmology. The company operates at a small scale with minimal public financial disclosure.
Profile data last refreshed 1h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Zilia?
AI assessmentZilia presents a high-risk, early-stage opportunity suitable only for mission-driven founders or specialists seeking ground-floor equity upside in ophthalmology diagnostics, not for those seeking stable career progression or clear market validation.
Why Work Here
- Early-stage device company in ophthalmology with potential to establish proprietary diagnostic platforms in retinal disease assessment.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Zilia Ocular
Retinal VascularClinical Trials (1)
NCT04408677Normative Data Collection Study of the Zilia Ocular for the Measurement of Oxygen Saturation in the Retina
N/AHelp build intelligence for Zilia
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.